Member Info for grizzlyb

Unusually specific Phil.

Have you been able to find the full document?

Shares have been bought by existing and new investors. It's illogical to place shares prior to imminent good news, if your intention is to dilute as little as possible.

The board chose a small and heavily discounted issue on AIM over a dual listing on NASDAQ. I'd suggest that listing on NASDAQ would have boosted the price. A continued reliance on AIM does not give me confidence in the business.

The market appears to agree.

Yes £9, and more, is possible, that's why I'm here. But in the previous message it appeared to be an arbitrary valuation. For balance, it could also be worth 9p.

How do you arrive at a £9 valuation? That differs to Edison's valuation, and they're paid £50k/annum by ReNeuron to come up with these things!

Also this article in Businessweek yesterday:

Vaccines Are Coming, But There’s No Such Hope for My Blindness ["https://www.bloomberg.com/news/articles/2020-11-25/a-covid-vaccine-is-coming-but-not-a-miracle-for-blindness-michael-schuman"]

Phil, you have to log on via. the website rather than app with HL.

Open your SIPP or investment account, and on the ReNeuron open offer row, click on the box with a tick.

Agreed.

All patients impact the score, not just the 8th patient, so one or more of the patients may have seen an improvement in the treated eye between 9 and 12 months, or just one patient may have a significant improvement in the treated eye. Conversely the untreated eyes may have deteriorated significantly between 9 and 12 months, resulting in a greater difference between treated and untreated.

8 patients have reached 9 months, mean difference between treated and untreated = 5.9 letters.

Of those 8 patients, 7 have also reached 12 months, mean difference between treated and untreated = 12.3 letters.

Of those 7 patients, 2 have also reached 18 months. Christ knows how one of those two is +22 in the untreated eye but currently that gives a mean difference of 0 letters. The differential at 18 months should improve as more patients reach that milestone.

I noticed the use of partners too, that would be significant. They've previously said the stroke programme will continue through regional partnerships . Will, rather than may. But if that's the case, why are we raising at 70p, positive stroke news would significant increase the valuation.

• After all this time, 70p is a fair old discount and suggests, to me, no further good news imminent

• £1.6 mil for RP IVT pre-clinical programme. Is IVT intravitreal à la jCell? Pre-clinical only so significant costs to follow

• Two patients have so far been assessed at 18 months:
Patient One: + 17 letters in treated eye, +1 letter in untreated eye, Patient Two: +6 letters in treated eye, + 22 letters in UNTREATED eye...HUH?

• Why no US capital raise?

• Interim results to be announced tomorrow.

But not at 1p, that would be pointless.

MH said in his recent Shares presentation that orphan drug designation would confer market exclusivity if they get through to market, 'provided no better alternatives exist when we get there'.

jCyte have a slot at AAO next week via. one of their investigators, haven't been able to find one for ReNeuron though.

I asked Buchanan a while ago if jCyte could get market exclusivity for RP, or whether the different methods of treatment would allow ReNeuron and jCyte to both get exclusivity for their respective methods - no response received.

I fear exclusivity is for indication rather than method of treatment.

https://www.genengnews.com/topics/translational-medicine/the-true-if-circuitous-path-to-stem-cell-cures/

That was my interpretation also. Doesn't seem very sensible to use the same chart for both eyes

https://vimeo.com/473444738?ref=em-v-share

Of note, much of the Day 365 untreated eye improvement is from 1 patient.

Well that's meaningless. Elaborate.

But he's also said the stroke programme will continue with regional partnerships and I'm yet to see any evidence of that...